Anti-CLDN18.2 heavy chain antibody, related product and application

The invention discloses an anti-CLDN18.2 heavy chain antibody, a related product and application of the anti-CLDN18.2 heavy chain antibody. The heavy-chain antibody is composed of a heavy-chain variable region, the amino acid sequence of CDR1 of the heavy-chain variable region comprises a sequence s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	YU XUEJUN, CHEN XIN, DI SHENGMENG, ZHANG SHIWEI, LI ZHAORUN, MA HENG, FENG DONGGE, FAN YANQIU
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention discloses an anti-CLDN18.2 heavy chain antibody, a related product and application of the anti-CLDN18.2 heavy chain antibody. The heavy-chain antibody is composed of a heavy-chain variable region, the amino acid sequence of CDR1 of the heavy-chain variable region comprises a sequence shown in SEQ ID No.2, the amino acid sequence of CDR2 of the heavy-chain variable region comprises a sequence shown in SEQ ID No.8, and the amino acid sequence of CDR3 of the heavy-chain variable region comprises a sequence shown in SEQ ID No.14. The anti-CLDN18.2 heavy chain antibody provided by the invention only comprises a heavy chain variable region, has high affinity and specificity, can efficiently target a CLDN18.2 antigen, does not recognize CLDN18.1, and is simple in structure and easy to prepare. In addition, the CAR-T cell prepared by using the CAR-T cell can specifically recognize CLDN18.2 positive tumor cells, and can also release various cytokines to efficiently kill the tumor cells. 本申请公开了一种抗CLDN18.2